RiboPro raises €1.2M to become leader in (m)RNA
RiboPro announced it has successfully closed a funding round of €1.2 million, led by Stichting Vlasroot
Read moreRiboPro and Pleco Therapeutics are semi-finalists of the pitch contest on 8 April
RiboPro (a spin-off from Mecurna), and Pleco Therapeutics pitched and won a place in the semi-finals at the Global Investor Forum 2021
Read moreCitryll Appoints Chief Medical Officer
Citryll announced it has appointed Patrick Round as Chief Medical Officer. Patrick will provide leadership and direction to Clinical development strategy, Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management/ Biometrics, and Drug Safety.
Read moreNederlandse capaciteit voor vullen van vaccinflesjes onbenut, experts bezorgd
Onlangs noemde Hans Schikan in FD het een van de bottlenecks van de Nederlandse vaccinstrategie; de vulcapaciteit. De oplossing, die is te vinden in Brabant bij BioConnection B.V. op Pivot Park.
Read moreGlycostem enters into Material Transfer Agreement with Pieris to enhance solid tumor targeting capabilities of Glycostem’s oNKord® and CAR-NK treatments
Under the terms of the agreement, Pieris will provide Glycostem with Anticalin constructs against immune targets to be combined with Glycostem’s oNKord® technology to study the combined potential of the technologies in the treatment of solid tumors.
Read moreThe Netherlands is putting its mark on the map of innovative pharmacy
Innovation within the pharmaceutical sector. This topic was discussed more than ever in 2020-2021.
Read moreELF paper selected for print in a special issue of SLAS Discovery
European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening.
Read morePharmSupport and the HAN developed a post-graduate course
Pivot Park gaat intensief samenwerken met de Hogeschool van Arnhem en Nijmegen (HAN).
Read more